Klara Z. Bakhtiyarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Klara Z. Bakhtiyarova has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Oscar V. Lyutov
Bashkir State Medical University
13 shared publications - Mansur Amirovich Kutlubaev
Bashkir State Medical University, Ministry of Health of Russia
11 shared publications - Аleksey N. Boyko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
10 shared publications - Nadezhda A. Malkova
International Tomography Center, Siberian Branch of the Russian Academy of Sciences
9 shared publications - Zoya Alexandrovna Goncharova
Rostov State Medical University, Ministry of Health of Russia
8 shared publications - Denis S. Korobko
Novosibirsk State Regional Clinical Hospital; Novosibirsk State Medical University
7 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 31 (4) , 46–55
Posterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome (PRES) condition attracts the close attention of neurologists, obstetricians and gynecologists, intensive care specialists and specialists in related fields. The relevance of studying PRES is due to the widespread prevalence of the syndrome in clinical practice and the variety of its manifestations. The clinical picture of PRES is characterized by polymorphism. Patients often experience: impaired consciousness, intense headache, epileptic seizures. Visual disorders are also characteristic — blurred vision, hemianopia. Nausea and vomiting are often noted, and in some cases, focal neurological symptoms. The pathogenetic basis of the syndrome is vasogenic cerebral edema, mainly affecting the parietal occipital regions. The etiology of the syndrome is very diverse: the leading provoking factors include sudden rises in blood pressure, preeclampsia and eclampsia, renal failure, immunosuppressive therapy, infectious and septic conditions, as well as electrolyte disorders. The diagnosis of PRES is based on the analysis of the clinical picture, neuroimaging data. The therapeutic strategy primarily involves correcting the root cause, such as normalization of blood pressure, preeclampsia delivery, or withdrawal of toxic drugs. Along with this, symptomatic therapy is carried out. as well as dynamic monitoring of neurological status. The prognosis with timely diagnosis and adequate treatment is favorable in most cases. This paper presents clinical observations of PRES in 23 and 24-year-old patients with preeclampsia, as well as in a 25-year-old patient with hemorrhagic fever and renal syndrome. The purpose of the description is to demonstrate the variability of etiological factors and the common pathogenetic mechanisms of the syndrome, as well as to emphasize the importance of a multidisciplinary approach to diagnosis and treatment.
- 27 October 2026
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 31 (4) , 46–55
Open AccessPosterior reversible encephalopathy syndrome
Posterior reversible encephalopathy syndrome (PRES) condition attracts the close attention of neurologists, obstetricians and gynecologists, intensive care specialists and specialists in related fields. The relevance of studying PRES is due to the widespread prevalence of the syndrome in clinical practice and the variety of its manifestations. The clinical picture of PRES is characterized by polymorphism. Patients often experience: impaired consciousness, intense headache, epileptic seizures. Visual disorders are also characteristic — blurred vision, hemianopia. Nausea and vomiting are often noted, and in some cases, focal neurological symptoms. The pathogenetic basis of the syndrome is vasogenic cerebral edema, mainly affecting the parietal occipital regions. The etiology of the syndrome is very diverse: the leading provoking factors include sudden rises in blood pressure, preeclampsia and eclampsia, renal failure, immunosuppressive therapy, infectious and septic conditions, as well as electrolyte disorders. The diagnosis of PRES is based on the analysis of the clinical picture, neuroimaging data. The therapeutic strategy primarily involves correcting the root cause, such as normalization of blood pressure, preeclampsia delivery, or withdrawal of toxic drugs. Along with this, symptomatic therapy is carried out. as well as dynamic monitoring of neurological status. The prognosis with timely diagnosis and adequate treatment is favorable in most cases. This paper presents clinical observations of PRES in 23 and 24-year-old patients with preeclampsia, as well as in a 25-year-old patient with hemorrhagic fever and renal syndrome. The purpose of the description is to demonstrate the variability of etiological factors and the common pathogenetic mechanisms of the syndrome, as well as to emphasize the importance of a multidisciplinary approach to diagnosis and treatment.
- Open Access
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 91-97
Diagnostic features of the neuromyelitis optica spectrum disorders in real clinical practice
Neuromyelitis optica spectrum disorders (NMOSD) constitute a group of rare, autoimmune and often disabling diseases of the central nervous system. Despite clear diagnostic criteria for NMOSD, diagnostic errors remain a serious problem, leading to delays in necessary treatment and adverse outcomes. This article presents four clinical cases of NMOSD that illustrate the difficulties in making a timely diagnosis due to an ambiguous clinical, radiological and laboratory picture. In these cases, clinical manifestations typical of NMOSD (optic neuritis, acute myelitis and area postrema syndrome) are described; however, the patients were initially referred to specialists in other fields: ophthalmologists, gastroenterologists and neurosurgeons, which led to a delay in their referral to the Multiple Sclerosis Centre and a late diagnosis. The delayed initiation of pathogenetic therapy in two patients led to the development of persistent severe disability as a consequence of NMOSD exacerbations. Factors contributing to the prolonged time to diagnosis were analyzed, and strategies to improve the early diagnosis of NMOSD to prevent such outcomes were proposed.
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 91-97
Open AccessDiagnostic features of the neuromyelitis optica spectrum disorders in real clinical practice
Neuromyelitis optica spectrum disorders (NMOSD) constitute a group of rare, autoimmune and often disabling diseases of the central nervous system. Despite clear diagnostic criteria for NMOSD, diagnostic errors remain a serious problem, leading to delays in necessary treatment and adverse outcomes. This article presents four clinical cases of NMOSD that illustrate the difficulties in making a timely diagnosis due to an ambiguous clinical, radiological and laboratory picture. In these cases, clinical manifestations typical of NMOSD (optic neuritis, acute myelitis and area postrema syndrome) are described; however, the patients were initially referred to specialists in other fields: ophthalmologists, gastroenterologists and neurosurgeons, which led to a delay in their referral to the Multiple Sclerosis Centre and a late diagnosis. The delayed initiation of pathogenetic therapy in two patients led to the development of persistent severe disability as a consequence of NMOSD exacerbations. Factors contributing to the prolonged time to diagnosis were analyzed, and strategies to improve the early diagnosis of NMOSD to prevent such outcomes were proposed.
- Open Access
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 103-110
Immune thrombocytopenic purpura in multiple sclerosis (clinical cases)
Immune thrombocytopenia (idiopathic thrombocytopenic purpura, ITP) and multiple sclerosis (MS) are two autoimmune diseases (AIDs), and their co-occurrence in a single patient is a rare combination. In recent years, there has been an increase in the prevalence of MS, as well as other AIDs; consequently, comorbid autoimmune conditions in individuals with MS are being observed with increasing frequency and are taking on significant scientific and clinical importance. Managing such patients is particularly challenging, as there is currently no established treatment strategy for patients with MS and concomitant ITP. The scientific literature describes isolated cases of the combination of MS and autoimmune thrombocytopenia, which may indicate shared pathogenetic mechanisms underlying these diseases. This article presents clinical cases illustrating two types of relationship between ITP and MS: primary autoimmune comorbidity of the conditions and secondary druginduced ITP. The widespread use in recent years of disease-modifying drugs (DMDs) and the planned expansion of their spectrum necessitate the stratification of the risks associated with this therapy.
- 18 August 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (4) , 103-110
Open AccessImmune thrombocytopenic purpura in multiple sclerosis (clinical cases)
Immune thrombocytopenia (idiopathic thrombocytopenic purpura, ITP) and multiple sclerosis (MS) are two autoimmune diseases (AIDs), and their co-occurrence in a single patient is a rare combination. In recent years, there has been an increase in the prevalence of MS, as well as other AIDs; consequently, comorbid autoimmune conditions in individuals with MS are being observed with increasing frequency and are taking on significant scientific and clinical importance. Managing such patients is particularly challenging, as there is currently no established treatment strategy for patients with MS and concomitant ITP. The scientific literature describes isolated cases of the combination of MS and autoimmune thrombocytopenia, which may indicate shared pathogenetic mechanisms underlying these diseases. This article presents clinical cases illustrating two types of relationship between ITP and MS: primary autoimmune comorbidity of the conditions and secondary druginduced ITP. The widespread use in recent years of disease-modifying drugs (DMDs) and the planned expansion of their spectrum necessitate the stratification of the risks associated with this therapy.
- Open Access
- 22 February 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (1) , 49-56
The impact of multiple sclerosis on life expectancy (the experience of the Republic of Bashkortostan)
The results of the first analysis of life expectancy, mortality, and causes of death in patients with multiple sclerosis (MS) in the Republic of Bashkortostan (RB) are presented. Objective: to study life expectancy indicators and mortality patterns among MS patients in the RB. Material and methods. The assessment of indicators was based on data from the Republican Centre for MS (RCMS) registry at the G. G. Kuvatov Republican Clinical Hospital for the period 2005–2023. During this period, 2,967 patients (10,303 person-years) were treated at the RCMS, of whom 297 died. Life expectancy was assessed using the Gehan–Breslow test. Standardised mortality rates (SMR) were calculated. The causes of death were determined based on information from the Republican Medical Information and Analytical System of the RB. Results. In more than 70 % of cases, the cause of death may be related to MS and its complications. The overall SMR rate among patients was 1.92. The average life expectancy of MS patients is 19.1 years shorter than that of the general population. The median survival rate of patients was 32 years on average. The average life expectancy for women with MS was significantly higher than for men. Conclusion. In the RB, the presence of MS increases the risk of premature death and reduces the patient's life expectancy. The indicators studied in the republic reflect global patterns and trends.
- 22 February 2026
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 18 (1) , 49-56
Open AccessThe impact of multiple sclerosis on life expectancy (the experience of the Republic of Bashkortostan)
The results of the first analysis of life expectancy, mortality, and causes of death in patients with multiple sclerosis (MS) in the Republic of Bashkortostan (RB) are presented. Objective: to study life expectancy indicators and mortality patterns among MS patients in the RB. Material and methods. The assessment of indicators was based on data from the Republican Centre for MS (RCMS) registry at the G. G. Kuvatov Republican Clinical Hospital for the period 2005–2023. During this period, 2,967 patients (10,303 person-years) were treated at the RCMS, of whom 297 died. Life expectancy was assessed using the Gehan–Breslow test. Standardised mortality rates (SMR) were calculated. The causes of death were determined based on information from the Republican Medical Information and Analytical System of the RB. Results. In more than 70 % of cases, the cause of death may be related to MS and its complications. The overall SMR rate among patients was 1.92. The average life expectancy of MS patients is 19.1 years shorter than that of the general population. The median survival rate of patients was 32 years on average. The average life expectancy for women with MS was significantly higher than for men. Conclusion. In the RB, the presence of MS increases the risk of premature death and reduces the patient's life expectancy. The indicators studied in the republic reflect global patterns and trends.
- Open Access
- 9 December 2025
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVII (4) , 321-330
Impact of multiple sclerosis on life expectancy: a review
BACKGROUND: In recent years, increasing attention has been paid to the quality of life and life expectancy of patients with multiple sclerosis. The influence of various factors related to the disease and its course, pharmacologic treatments, and comorbid conditions on patient longevity has been actively studied, as life expectancy is considered a key indicator of therapeutic success. AIM: Review of current data on disease duration, mortality and its causes in patients with multiple sclerosis. METHODS: This review was based on materials from Russian and international scientific literature databases, including the electronic scientific library CyberLeninka, the Medline bibliographic database, the national electronic library eLibrary, and the abstracting and indexing databases Scopus, SpringerLink, and PubMed. Publications from the past 5–10 years were analyzed, including systematic reviews, case reports, and original research articles. The search was conducted using the following keywords: рассеянный склероз / multiple sclerosis, продолжительность жизни / life expectancy, выживаемость (survival), смертность/mortality, причины смертности / risk factors. RESULTS: Life expectancy in patients with multiple sclerosis is reduced by approximately 6–10 years, and mortality associated with this condition is significantly higher compared with that in the general population. Individuals with multiple sclerosis demonstrate decreased overall survival and an increased risk of death from cardiovascular, respiratory, and infectious diseases, as well as from accidents and suicide. CONCLUSION: Multiple sclerosis substantially affects life expectancy and increases the risk of premature death in patients. Long-term prognostication of disease progression remains challenging due to the limitations, fragmentation, and incompleteness of available data. Further research is needed, as identifying and understanding the risk factors for premature death are essential for ensuring timely and effective medical care throughout the course of the disease.
- 9 December 2025
- Published by ECO-Vector LLC (Publications) in Neurology Bulletin
- Vol. LVII (4) , 321-330
Open AccessImpact of multiple sclerosis on life expectancy: a review
BACKGROUND: In recent years, increasing attention has been paid to the quality of life and life expectancy of patients with multiple sclerosis. The influence of various factors related to the disease and its course, pharmacologic treatments, and comorbid conditions on patient longevity has been actively studied, as life expectancy is considered a key indicator of therapeutic success. AIM: Review of current data on disease duration, mortality and its causes in patients with multiple sclerosis. METHODS: This review was based on materials from Russian and international scientific literature databases, including the electronic scientific library CyberLeninka, the Medline bibliographic database, the national electronic library eLibrary, and the abstracting and indexing databases Scopus, SpringerLink, and PubMed. Publications from the past 5–10 years were analyzed, including systematic reviews, case reports, and original research articles. The search was conducted using the following keywords: рассеянный склероз / multiple sclerosis, продолжительность жизни / life expectancy, выживаемость (survival), смертность/mortality, причины смертности / risk factors. RESULTS: Life expectancy in patients with multiple sclerosis is reduced by approximately 6–10 years, and mortality associated with this condition is significantly higher compared with that in the general population. Individuals with multiple sclerosis demonstrate decreased overall survival and an increased risk of death from cardiovascular, respiratory, and infectious diseases, as well as from accidents and suicide. CONCLUSION: Multiple sclerosis substantially affects life expectancy and increases the risk of premature death in patients. Long-term prognostication of disease progression remains challenging due to the limitations, fragmentation, and incompleteness of available data. Further research is needed, as identifying and understanding the risk factors for premature death are essential for ensuring timely and effective medical care throughout the course of the disease.
- Open Access
- 20 October 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (5) , 11-20
Results of medical and social research and assessment of quality of life in myasthenia gravis
Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.
- 20 October 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (5) , 11-20
Open AccessResults of medical and social research and assessment of quality of life in myasthenia gravis
Myasthenia gravis (MG) is one of the most common autoimmune diseases of the nervous system. Medical and social analysis of the patient population structure and assessment of their quality of life (QoL) as one of the criteria for the effectiveness of treatment are of great importance for evaluating the condition of patients and the directions of development of specialised care.Objective: to analyse the quality of life of patients diagnosed with MG.Material and methods. The study involved 662 patients with MG from 26 regions of Russia. A specially designed medical and social questionnaire and the SF-36 questionnaire were used.Results. In Russia, women and middle-aged and elderly people predominate among MG patients. MG is characterised by a relatively favourable course (less than half of patients have any form of disability). Almost two-thirds of patients have other chronic diseases. About 90% of MG patients receive drug therapy, but almost half of patients have problems obtaining their prescribed medication. In addition to a significant decrease in physical activity, there is also a decrease in the mental state of patients associated with various physical disorders, as well as fear of the future (fear of symptom recurrence, risk of being left without support and unable to perform daily tasks, the need for lifelong treatment). Among the symptoms of MG that affect the emotional state of patients, weakness and rapid fatigue are in first place, followed by bulbar dysfunction. The role functioning of patients with MG depends to a greater extent on their physical condition and to a lesser extent on their emotional state. Those receiving regular drug therapy had significantly better indicators than those who were not treated. The SF-36 scale assessment confirmed that physical condition and physical functioning, which influence the psychological components of QoL assessment, are crucial for QoL in MG.Conclusion. A significant decrease in QoL indicators was noted in MG, primarily in the physical component and, secondarily, in psychological health. All this points to the need for early initiation of highly effective pathogenetic therapy, in particular with modern C5-complement inhibitors.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 124-130
Search for informative predictors of the development and progression of multiple sclerosis
Objective. To identify informative predictors of the development and progression of multiple sclerosis (MS) based on polygenic analysis of associations of polymorphic variants in the IL1R1, IL10, IL12B, IL2, IL2RA, and IL7R genes. Material and methods. The study included 247 patients with MS and 1271 control subjects. Associations of development and progression of MS with polymorphic variants of the IL1R1, IL10, IL12B, IL2, IL2RA, IL7, and IL7R genes were analyzed. The combinations of allelic variants associated with the disease were searched using the APSampler software, and predictive models of the development and progression of MS were developed using multifactorial logistic regression with step-by-step inclusion of variables. Results. The increased probability of MS was associated with the IL1R1 rs2287047 (recessive model, OR=2.2, pFDR=0.022), IL7R rs1494558 polymorphic variants (log additive model, OR=1.49, pFDR=0.003), and IL2RA rs12722580 *I/D genotype (codominant model, OR=1.67, pFDR=0.03). Reduced MS risk was associated with IL10 rs1800872 (recessive model, OR=0.38, pFDR=0.044), IL7R rs10624573 (dominant model, OR=0.67, pFDR=0.022), IL7R rs6897932 variants (recessive model, OR=0.21, pFDR=0.008), and IL2RA rs12722580 * D/D genotype (codominant model, OR=0.78, pFDR=0.03). Combinations (IL7R rs1494558*T+IL7R rs6897932*T, IL1R1 rs2287047*C+IL12B rs3212227*C and IL7R rs1494558*T/C+IL12B rs3212227*A) with a synergistic effect were identified, and predictive models of MS development and progression risk with a sufficiently high prognostic value were created. Conclusion. The results of the study emphasize the importance of polymorphic variants of IL7R, IL1R1, IL2RA, and IL10 in the genetic predisposition to MS. The obtained models require validation and can be supplemented with other predictors to improve accuracy; nevertheless, they demonstrate important pathogenetic patterns and directions for further study.
- 6 October 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (9) , 124-130
Search for informative predictors of the development and progression of multiple sclerosis
Objective. To identify informative predictors of the development and progression of multiple sclerosis (MS) based on polygenic analysis of associations of polymorphic variants in the IL1R1, IL10, IL12B, IL2, IL2RA, and IL7R genes. Material and methods. The study included 247 patients with MS and 1271 control subjects. Associations of development and progression of MS with polymorphic variants of the IL1R1, IL10, IL12B, IL2, IL2RA, IL7, and IL7R genes were analyzed. The combinations of allelic variants associated with the disease were searched using the APSampler software, and predictive models of the development and progression of MS were developed using multifactorial logistic regression with step-by-step inclusion of variables. Results. The increased probability of MS was associated with the IL1R1 rs2287047 (recessive model, OR=2.2, pFDR=0.022), IL7R rs1494558 polymorphic variants (log additive model, OR=1.49, pFDR=0.003), and IL2RA rs12722580 *I/D genotype (codominant model, OR=1.67, pFDR=0.03). Reduced MS risk was associated with IL10 rs1800872 (recessive model, OR=0.38, pFDR=0.044), IL7R rs10624573 (dominant model, OR=0.67, pFDR=0.022), IL7R rs6897932 variants (recessive model, OR=0.21, pFDR=0.008), and IL2RA rs12722580 * D/D genotype (codominant model, OR=0.78, pFDR=0.03). Combinations (IL7R rs1494558*T+IL7R rs6897932*T, IL1R1 rs2287047*C+IL12B rs3212227*C and IL7R rs1494558*T/C+IL12B rs3212227*A) with a synergistic effect were identified, and predictive models of MS development and progression risk with a sufficiently high prognostic value were created. Conclusion. The results of the study emphasize the importance of polymorphic variants of IL7R, IL1R1, IL2RA, and IL10 in the genetic predisposition to MS. The obtained models require validation and can be supplemented with other predictors to improve accuracy; nevertheless, they demonstrate important pathogenetic patterns and directions for further study.
- Open Access
- 23 September 2025
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (2) , 48-57
Clinical and epidemiological features of amyotrophic lateral sclerosis in the Republic of Bashkortostan (Russia)
Background. Amyotrophic lateral sclerosis (ALS) is a degenerative disease of the nervous system, the prevalence of which varies considerably in different regions of the world. Epidemiologic studies of ALS in the Russian Federation are scarce.Aim. To analyze the epidemiological features of ALS in the Republic of Bashkortostan (RB) according to the data of the unified state information system in the field of health care and clinical characteristics according to the hospital register for the period 2013–2024.Materials and methods. A retrospective analysis of electronic medical records of all patients living in the RB who were diagnosed with G12.2 according to the 10th revision of the International Classification of Diseases within analyzed period was performed. The study of clinical characteristics of patients with ALS was done using data from the hospital registry, which was maintained since 2013.Results. The primary incidence of ALS in RB increased from 0.7 to 1.1–1.3 cases per 100,000 population over the period 2013–2024. The overall incidence of ALS for this period increased more than 3-fold, from 0.8 to 2.7 cases per 100 thousand population. The first manifestations of the disease were more often noted at the age of 53–66 years, among patients prevailed rural residents (59.5 %), people of physical labor (48.3 %). Men were more often suffered from ALS in the group with onset before the age of 45 years (p = 0.028), women more often had bulbar form of the disease (p = 0.046). The diagnosis was established on average one year after the development of the first symptoms of the disease.Conclusion. There was an increase in the incidence of ALS over 2012–2024, which probably reflects improved detection of the disease in the RB. Future studies should clarify the role of environmental and biological factors in the development of ALS.
- 23 September 2025
- Published by Publishing House ABV Press in Neuromuscular Diseases
- Vol. 15 (2) , 48-57
Open AccessClinical and epidemiological features of amyotrophic lateral sclerosis in the Republic of Bashkortostan (Russia)
Background. Amyotrophic lateral sclerosis (ALS) is a degenerative disease of the nervous system, the prevalence of which varies considerably in different regions of the world. Epidemiologic studies of ALS in the Russian Federation are scarce.Aim. To analyze the epidemiological features of ALS in the Republic of Bashkortostan (RB) according to the data of the unified state information system in the field of health care and clinical characteristics according to the hospital register for the period 2013–2024.Materials and methods. A retrospective analysis of electronic medical records of all patients living in the RB who were diagnosed with G12.2 according to the 10th revision of the International Classification of Diseases within analyzed period was performed. The study of clinical characteristics of patients with ALS was done using data from the hospital registry, which was maintained since 2013.Results. The primary incidence of ALS in RB increased from 0.7 to 1.1–1.3 cases per 100,000 population over the period 2013–2024. The overall incidence of ALS for this period increased more than 3-fold, from 0.8 to 2.7 cases per 100 thousand population. The first manifestations of the disease were more often noted at the age of 53–66 years, among patients prevailed rural residents (59.5 %), people of physical labor (48.3 %). Men were more often suffered from ALS in the group with onset before the age of 45 years (p = 0.028), women more often had bulbar form of the disease (p = 0.046). The diagnosis was established on average one year after the development of the first symptoms of the disease.Conclusion. There was an increase in the incidence of ALS over 2012–2024, which probably reflects improved detection of the disease in the RB. Future studies should clarify the role of environmental and biological factors in the development of ALS.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 16-25
Open AccessDivozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders
Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 41-49
Clinical and social study and assessment of quality of life in patients with neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD, formerly known as opticoneuromyelitis or Devic's disease) are severe chronic autoimmune inflammatory diseases of the central nervous system (CNS) associated with high disability in the absence of adequate treatment. In Russia, no assessment of the medical and social characteristics of this disease and the quality of life of patients has been conducted, which complicates the assessment of the prognosis and the development of medical and social management strategies for these patients.Objective: to analyse the medical and social characteristics and quality of life of patients diagnosed with NMOSD (opticoneuromyelitis).Material and methods. The condition of patients with a confirmed diagnosis of NMOSD or opticoneuromyelitis was assessed using a specially designed questionnaire, which also included questions about patients' attitudes towards their health. The SF-36 international quality of life questionnaire was used to score quality of life. Based on the results of the study, 280 patients diagnosed with NMOSD were surveyed in 21 regions of the Russian Federation.Results. Most patients with NMOSD who are observed by neurologists receive specialised treatment, but half of all patients with NMOSD currently experience some difficulties in obtaining drug therapy. Over the past year, 28.6% of respondents reported an improvement in their health, 39.6% reported no change, and 31.8% reported a deterioration. Self-assessment of health status declines sharply in patients over 55 years of age. The majority (74%) of patients report a decline in vision. Every second patient noted a decrease in vision at the onset of the disease. Severe movement disorders are characteristic, and for the majority (91%) of patients with NMOSD, strenuous physical activities such as running and weight training are not possible. Patients with disability groups I or II are more limited in their physical and mental resources. Patients receiving treatment significantly better assess changes in their health over the past year, both physical and psychological. Those who receive specialized drug therapy have a much better perception of their own health and its prospects. The SF-36 quality of life indices for NMOSD are significantly lower than normal, primarily in terms of physical condition, but also in terms of psychological well-being.Conclusion. In NMOSD, there are pronounced changes in the quality of life of patients, both according to the original questionnaire and according to the SF-36 scale. Receiving timely and adequate treatment significantly improves these indicators and the prognosis.
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 41-49
Open AccessClinical and social study and assessment of quality of life in patients with neuromyelitis optica spectrum disorders
Neuromyelitis optica spectrum disorders (NMOSD, formerly known as opticoneuromyelitis or Devic's disease) are severe chronic autoimmune inflammatory diseases of the central nervous system (CNS) associated with high disability in the absence of adequate treatment. In Russia, no assessment of the medical and social characteristics of this disease and the quality of life of patients has been conducted, which complicates the assessment of the prognosis and the development of medical and social management strategies for these patients.Objective: to analyse the medical and social characteristics and quality of life of patients diagnosed with NMOSD (opticoneuromyelitis).Material and methods. The condition of patients with a confirmed diagnosis of NMOSD or opticoneuromyelitis was assessed using a specially designed questionnaire, which also included questions about patients' attitudes towards their health. The SF-36 international quality of life questionnaire was used to score quality of life. Based on the results of the study, 280 patients diagnosed with NMOSD were surveyed in 21 regions of the Russian Federation.Results. Most patients with NMOSD who are observed by neurologists receive specialised treatment, but half of all patients with NMOSD currently experience some difficulties in obtaining drug therapy. Over the past year, 28.6% of respondents reported an improvement in their health, 39.6% reported no change, and 31.8% reported a deterioration. Self-assessment of health status declines sharply in patients over 55 years of age. The majority (74%) of patients report a decline in vision. Every second patient noted a decrease in vision at the onset of the disease. Severe movement disorders are characteristic, and for the majority (91%) of patients with NMOSD, strenuous physical activities such as running and weight training are not possible. Patients with disability groups I or II are more limited in their physical and mental resources. Patients receiving treatment significantly better assess changes in their health over the past year, both physical and psychological. Those who receive specialized drug therapy have a much better perception of their own health and its prospects. The SF-36 quality of life indices for NMOSD are significantly lower than normal, primarily in terms of physical condition, but also in terms of psychological well-being.Conclusion. In NMOSD, there are pronounced changes in the quality of life of patients, both according to the original questionnaire and according to the SF-36 scale. Receiving timely and adequate treatment significantly improves these indicators and the prognosis.